Global Monkeypox Vaccine Market

Monkeypox Vaccine Comprehensive Study by Application (Adult, Child), Symptoms (Including Chills, Fever Headache, Muscle Weakness, Lymph Node Swelling, Exhaustion), End-use (Private Hospitals / Clinics, Government Hospital and Program) Players and Region - Global Market Outlook to 2027

Monkeypox Vaccine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Monkeypox is a viral zoonotic complaint that occurs primarily in tropical rainforest areas of central and West Africa and is sometimes exported to other regions. Monkeypox is caused by monkeypox contagion, a member of the Orthopoxvirus rubric in the family Poxviridae. Monkeypox is generally a tone-limited complaint with the symptoms lasting from 2 to 4 weeks. Severe cases can do. In recent times, the case casualty rate has been around 3 – 6. Monkeypox is transmitted to humans through close contact with an infected person or beast, or with material defiled with the contagion. Monkeypox contagion is transmitted from one person to another by close contact with lesions, body fluids, respiratory driblets and defiled accoutrements similar as coverlet. Monkeypox is less contagious than smallpox and causes less severe illness. Monkeypox generally presents clinically with fever, rash and blown lymph bumps and may lead to a range of medical complications.This growth is primarily driven by High Prevalence of Infectious Diseases .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitN
Value UnitValue (USD Million)
Key Companies in StudyEmergent BioSolutions Inc. (United States), Wyeth Laboratories, Inc. (United States), Bavarian Nordic (Denmark), Sanofi Pasteur Biologics LLC. (United States), Chimerix (United States), Nanotherapeutics (United States), SIGA Technologies (United States), TapImmune (United States), Tonix Pharmaceuticals Holding (United States) and CEL-SCI (United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Emergent BioSolutions Inc. (United States), Wyeth Laboratories, Inc. (United States), Bavarian Nordic (Denmark), Sanofi Pasteur Biologics LLC. (United States), Chimerix (United States), Nanotherapeutics (United States), SIGA Technologies (United States), TapImmune (United States), Tonix Pharmaceuticals Holding (United States) and CEL-SCI (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In 2022, Bavarian Nordic announced BARDA exercised the first options (119 million boluses) under the contract to supply a snap- dried interpretation of the JYNNEOS smallpox vaccine. The transfer of the snap- drying process to our new filler and finish factory in Kvistgaard was initiated last time and, following an FDA examination in 2022, will lead to marketable manufacturing in 2023. To date, the Company has supplied nearly 30 million boluses of the liquid- firmed interpretation to HHS, with the vast maturity being delivered for exigency use before blessing of the vaccine by the FDA in 2019. The FDA also granted Bavarian Nordic a Priority Review Voucher under the Material trouble Medical Countermeasure program.The market is concentrated with a limited number of global market players who are still in innovations with monkeypox vaccine against any emerging virus as a treatment and are closely working with the big institution to ensure a sufficient and rapid supply of additional vaccines.

Regulatory Insights:
JYNNEOS™ is approved by the Food and Drug Administration (FDA) for prevention of smallpox and monkeypox disease in adults 18 years or older at high risk for smallpox or monkeypox infection.

Market Drivers
  • High Prevalence of Infectious Diseases
  • Expanding focus on Immunization Programmes

Market Trend
  • Growth in R &D Activities to Develop New Vaccine

Restraints
  • Monkeypox Vaccine Caused Several Serious Adverse Events


Challenges
High-cost Investments for Vaccine Development

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Monkeypox Vaccine Study Sheds Light on
— The Monkeypox Vaccine Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Monkeypox Vaccine industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Monkeypox Vaccine industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Adult
  • Child
By Symptoms
  • Including Chills
  • Fever Headache
  • Muscle Weakness
  • Lymph Node Swelling
  • Exhaustion

By End-use
  • Private Hospitals / Clinics
  • Government Hospital and Program

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Infectious Diseases
      • 3.2.2. Expanding focus on Immunization Programmes
    • 3.3. Market Challenges
      • 3.3.1. High-cost Investments for Vaccine Development
    • 3.4. Market Trends
      • 3.4.1. Growth in R &D Activities to Develop New Vaccine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Monkeypox Vaccine, by Application, Symptoms, End-use and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Monkeypox Vaccine (Value)
      • 5.2.1. Global Monkeypox Vaccine by: Application (Value)
        • 5.2.1.1. Adult
        • 5.2.1.2. Child
      • 5.2.2. Global Monkeypox Vaccine by: Symptoms (Value)
        • 5.2.2.1. Including Chills
        • 5.2.2.2. Fever Headache
        • 5.2.2.3. Muscle Weakness
        • 5.2.2.4. Lymph Node Swelling
        • 5.2.2.5. Exhaustion
      • 5.2.3. Global Monkeypox Vaccine by: End-use (Value)
        • 5.2.3.1. Private Hospitals / Clinics
        • 5.2.3.2. Government Hospital and Program
      • 5.2.4. Global Monkeypox Vaccine Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Monkeypox Vaccine (Volume)
      • 5.3.1. Global Monkeypox Vaccine by: Application (Volume)
        • 5.3.1.1. Adult
        • 5.3.1.2. Child
      • 5.3.2. Global Monkeypox Vaccine by: Symptoms (Volume)
        • 5.3.2.1. Including Chills
        • 5.3.2.2. Fever Headache
        • 5.3.2.3. Muscle Weakness
        • 5.3.2.4. Lymph Node Swelling
        • 5.3.2.5. Exhaustion
      • 5.3.3. Global Monkeypox Vaccine by: End-use (Volume)
        • 5.3.3.1. Private Hospitals / Clinics
        • 5.3.3.2. Government Hospital and Program
      • 5.3.4. Global Monkeypox Vaccine Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Monkeypox Vaccine (Price)
  • 6. Monkeypox Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Emergent BioSolutions Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Wyeth Laboratories, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bavarian Nordic (Denmark)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi Pasteur Biologics LLC. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Chimerix (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Nanotherapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. SIGA Technologies (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. TapImmune (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Tonix Pharmaceuticals Holding (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CEL-SCI (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Monkeypox Vaccine Sale, by Application, Symptoms, End-use and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Monkeypox Vaccine (Value)
      • 7.2.1. Global Monkeypox Vaccine by: Application (Value)
        • 7.2.1.1. Adult
        • 7.2.1.2. Child
      • 7.2.2. Global Monkeypox Vaccine by: Symptoms (Value)
        • 7.2.2.1. Including Chills
        • 7.2.2.2. Fever Headache
        • 7.2.2.3. Muscle Weakness
        • 7.2.2.4. Lymph Node Swelling
        • 7.2.2.5. Exhaustion
      • 7.2.3. Global Monkeypox Vaccine by: End-use (Value)
        • 7.2.3.1. Private Hospitals / Clinics
        • 7.2.3.2. Government Hospital and Program
      • 7.2.4. Global Monkeypox Vaccine Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Monkeypox Vaccine (Volume)
      • 7.3.1. Global Monkeypox Vaccine by: Application (Volume)
        • 7.3.1.1. Adult
        • 7.3.1.2. Child
      • 7.3.2. Global Monkeypox Vaccine by: Symptoms (Volume)
        • 7.3.2.1. Including Chills
        • 7.3.2.2. Fever Headache
        • 7.3.2.3. Muscle Weakness
        • 7.3.2.4. Lymph Node Swelling
        • 7.3.2.5. Exhaustion
      • 7.3.3. Global Monkeypox Vaccine by: End-use (Volume)
        • 7.3.3.1. Private Hospitals / Clinics
        • 7.3.3.2. Government Hospital and Program
      • 7.3.4. Global Monkeypox Vaccine Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Monkeypox Vaccine (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Monkeypox Vaccine: by Application(USD Million)
  • Table 2. Monkeypox Vaccine Adult , by Region USD Million (2016-2021)
  • Table 3. Monkeypox Vaccine Child , by Region USD Million (2016-2021)
  • Table 4. Monkeypox Vaccine: by Symptoms(USD Million)
  • Table 5. Monkeypox Vaccine Including Chills , by Region USD Million (2016-2021)
  • Table 6. Monkeypox Vaccine Fever Headache , by Region USD Million (2016-2021)
  • Table 7. Monkeypox Vaccine Muscle Weakness , by Region USD Million (2016-2021)
  • Table 8. Monkeypox Vaccine Lymph Node Swelling , by Region USD Million (2016-2021)
  • Table 9. Monkeypox Vaccine Exhaustion , by Region USD Million (2016-2021)
  • Table 10. Monkeypox Vaccine: by End-use(USD Million)
  • Table 11. Monkeypox Vaccine Private Hospitals / Clinics , by Region USD Million (2016-2021)
  • Table 12. Monkeypox Vaccine Government Hospital and Program , by Region USD Million (2016-2021)
  • Table 13. South America Monkeypox Vaccine, by Country USD Million (2016-2021)
  • Table 14. South America Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 15. South America Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 16. South America Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 17. Brazil Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 18. Brazil Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 19. Brazil Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 20. Argentina Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 21. Argentina Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 22. Argentina Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 23. Rest of South America Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 24. Rest of South America Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 25. Rest of South America Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 26. Asia Pacific Monkeypox Vaccine, by Country USD Million (2016-2021)
  • Table 27. Asia Pacific Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 28. Asia Pacific Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 29. Asia Pacific Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 30. China Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 31. China Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 32. China Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 33. Japan Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 34. Japan Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 35. Japan Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 36. India Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 37. India Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 38. India Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 39. South Korea Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 40. South Korea Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 41. South Korea Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 42. Taiwan Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 43. Taiwan Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 44. Taiwan Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 45. Australia Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 46. Australia Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 47. Australia Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 51. Europe Monkeypox Vaccine, by Country USD Million (2016-2021)
  • Table 52. Europe Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 53. Europe Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 54. Europe Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 55. Germany Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 56. Germany Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 57. Germany Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 58. France Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 59. France Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 60. France Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 61. Italy Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 62. Italy Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 63. Italy Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 64. United Kingdom Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 65. United Kingdom Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 66. United Kingdom Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 67. Rest of Europe Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 68. Rest of Europe Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 69. Rest of Europe Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 70. MEA Monkeypox Vaccine, by Country USD Million (2016-2021)
  • Table 71. MEA Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 72. MEA Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 73. MEA Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 74. Middle East Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 75. Middle East Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 76. Middle East Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 77. Africa Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 78. Africa Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 79. Africa Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 80. North America Monkeypox Vaccine, by Country USD Million (2016-2021)
  • Table 81. North America Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 82. North America Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 83. North America Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 84. United States Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 85. United States Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 86. United States Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 87. Canada Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 88. Canada Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 89. Canada Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 90. Mexico Monkeypox Vaccine, by Application USD Million (2016-2021)
  • Table 91. Mexico Monkeypox Vaccine, by Symptoms USD Million (2016-2021)
  • Table 92. Mexico Monkeypox Vaccine, by End-use USD Million (2016-2021)
  • Table 93. Monkeypox Vaccine Sales: by Application(N)
  • Table 94. Monkeypox Vaccine Sales Adult , by Region N (2016-2021)
  • Table 95. Monkeypox Vaccine Sales Child , by Region N (2016-2021)
  • Table 96. Monkeypox Vaccine Sales: by Symptoms(N)
  • Table 97. Monkeypox Vaccine Sales Including Chills , by Region N (2016-2021)
  • Table 98. Monkeypox Vaccine Sales Fever Headache , by Region N (2016-2021)
  • Table 99. Monkeypox Vaccine Sales Muscle Weakness , by Region N (2016-2021)
  • Table 100. Monkeypox Vaccine Sales Lymph Node Swelling , by Region N (2016-2021)
  • Table 101. Monkeypox Vaccine Sales Exhaustion , by Region N (2016-2021)
  • Table 102. Monkeypox Vaccine Sales: by End-use(N)
  • Table 103. Monkeypox Vaccine Sales Private Hospitals / Clinics , by Region N (2016-2021)
  • Table 104. Monkeypox Vaccine Sales Government Hospital and Program , by Region N (2016-2021)
  • Table 105. South America Monkeypox Vaccine Sales, by Country N (2016-2021)
  • Table 106. South America Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 107. South America Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 108. South America Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 109. Brazil Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 110. Brazil Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 111. Brazil Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 112. Argentina Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 113. Argentina Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 114. Argentina Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 115. Rest of South America Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 116. Rest of South America Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 117. Rest of South America Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 118. Asia Pacific Monkeypox Vaccine Sales, by Country N (2016-2021)
  • Table 119. Asia Pacific Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 120. Asia Pacific Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 121. Asia Pacific Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 122. China Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 123. China Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 124. China Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 125. Japan Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 126. Japan Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 127. Japan Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 128. India Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 129. India Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 130. India Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 131. South Korea Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 132. South Korea Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 133. South Korea Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 134. Taiwan Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 135. Taiwan Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 136. Taiwan Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 137. Australia Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 138. Australia Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 139. Australia Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 140. Rest of Asia-Pacific Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 141. Rest of Asia-Pacific Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 142. Rest of Asia-Pacific Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 143. Europe Monkeypox Vaccine Sales, by Country N (2016-2021)
  • Table 144. Europe Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 145. Europe Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 146. Europe Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 147. Germany Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 148. Germany Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 149. Germany Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 150. France Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 151. France Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 152. France Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 153. Italy Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 154. Italy Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 155. Italy Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 156. United Kingdom Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 157. United Kingdom Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 158. United Kingdom Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 159. Rest of Europe Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 160. Rest of Europe Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 161. Rest of Europe Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 162. MEA Monkeypox Vaccine Sales, by Country N (2016-2021)
  • Table 163. MEA Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 164. MEA Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 165. MEA Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 166. Middle East Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 167. Middle East Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 168. Middle East Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 169. Africa Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 170. Africa Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 171. Africa Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 172. North America Monkeypox Vaccine Sales, by Country N (2016-2021)
  • Table 173. North America Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 174. North America Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 175. North America Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 176. United States Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 177. United States Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 178. United States Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 179. Canada Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 180. Canada Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 181. Canada Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 182. Mexico Monkeypox Vaccine Sales, by Application N (2016-2021)
  • Table 183. Mexico Monkeypox Vaccine Sales, by Symptoms N (2016-2021)
  • Table 184. Mexico Monkeypox Vaccine Sales, by End-use N (2016-2021)
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Monkeypox Vaccine: by Application(USD Million)
  • Table 196. Monkeypox Vaccine Adult , by Region USD Million (2022-2027)
  • Table 197. Monkeypox Vaccine Child , by Region USD Million (2022-2027)
  • Table 198. Monkeypox Vaccine: by Symptoms(USD Million)
  • Table 199. Monkeypox Vaccine Including Chills , by Region USD Million (2022-2027)
  • Table 200. Monkeypox Vaccine Fever Headache , by Region USD Million (2022-2027)
  • Table 201. Monkeypox Vaccine Muscle Weakness , by Region USD Million (2022-2027)
  • Table 202. Monkeypox Vaccine Lymph Node Swelling , by Region USD Million (2022-2027)
  • Table 203. Monkeypox Vaccine Exhaustion , by Region USD Million (2022-2027)
  • Table 204. Monkeypox Vaccine: by End-use(USD Million)
  • Table 205. Monkeypox Vaccine Private Hospitals / Clinics , by Region USD Million (2022-2027)
  • Table 206. Monkeypox Vaccine Government Hospital and Program , by Region USD Million (2022-2027)
  • Table 207. South America Monkeypox Vaccine, by Country USD Million (2022-2027)
  • Table 208. South America Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 209. South America Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 210. South America Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 211. Brazil Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 212. Brazil Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 213. Brazil Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 214. Argentina Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 215. Argentina Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 216. Argentina Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 217. Rest of South America Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 218. Rest of South America Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 219. Rest of South America Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 220. Asia Pacific Monkeypox Vaccine, by Country USD Million (2022-2027)
  • Table 221. Asia Pacific Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 222. Asia Pacific Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 223. Asia Pacific Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 224. China Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 225. China Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 226. China Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 227. Japan Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 228. Japan Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 229. Japan Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 230. India Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 231. India Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 232. India Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 233. South Korea Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 234. South Korea Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 235. South Korea Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 236. Taiwan Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 237. Taiwan Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 238. Taiwan Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 239. Australia Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 240. Australia Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 241. Australia Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 242. Rest of Asia-Pacific Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 243. Rest of Asia-Pacific Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 244. Rest of Asia-Pacific Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 245. Europe Monkeypox Vaccine, by Country USD Million (2022-2027)
  • Table 246. Europe Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 247. Europe Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 248. Europe Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 249. Germany Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 250. Germany Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 251. Germany Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 252. France Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 253. France Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 254. France Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 255. Italy Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 256. Italy Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 257. Italy Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 258. United Kingdom Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 259. United Kingdom Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 260. United Kingdom Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 261. Rest of Europe Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 262. Rest of Europe Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 263. Rest of Europe Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 264. MEA Monkeypox Vaccine, by Country USD Million (2022-2027)
  • Table 265. MEA Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 266. MEA Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 267. MEA Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 268. Middle East Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 269. Middle East Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 270. Middle East Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 271. Africa Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 272. Africa Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 273. Africa Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 274. North America Monkeypox Vaccine, by Country USD Million (2022-2027)
  • Table 275. North America Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 276. North America Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 277. North America Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 278. United States Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 279. United States Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 280. United States Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 281. Canada Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 282. Canada Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 283. Canada Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 284. Mexico Monkeypox Vaccine, by Application USD Million (2022-2027)
  • Table 285. Mexico Monkeypox Vaccine, by Symptoms USD Million (2022-2027)
  • Table 286. Mexico Monkeypox Vaccine, by End-use USD Million (2022-2027)
  • Table 287. Monkeypox Vaccine Sales: by Application(N)
  • Table 288. Monkeypox Vaccine Sales Adult , by Region N (2022-2027)
  • Table 289. Monkeypox Vaccine Sales Child , by Region N (2022-2027)
  • Table 290. Monkeypox Vaccine Sales: by Symptoms(N)
  • Table 291. Monkeypox Vaccine Sales Including Chills , by Region N (2022-2027)
  • Table 292. Monkeypox Vaccine Sales Fever Headache , by Region N (2022-2027)
  • Table 293. Monkeypox Vaccine Sales Muscle Weakness , by Region N (2022-2027)
  • Table 294. Monkeypox Vaccine Sales Lymph Node Swelling , by Region N (2022-2027)
  • Table 295. Monkeypox Vaccine Sales Exhaustion , by Region N (2022-2027)
  • Table 296. Monkeypox Vaccine Sales: by End-use(N)
  • Table 297. Monkeypox Vaccine Sales Private Hospitals / Clinics , by Region N (2022-2027)
  • Table 298. Monkeypox Vaccine Sales Government Hospital and Program , by Region N (2022-2027)
  • Table 299. South America Monkeypox Vaccine Sales, by Country N (2022-2027)
  • Table 300. South America Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 301. South America Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 302. South America Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 303. Brazil Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 304. Brazil Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 305. Brazil Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 306. Argentina Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 307. Argentina Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 308. Argentina Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 309. Rest of South America Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 310. Rest of South America Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 311. Rest of South America Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 312. Asia Pacific Monkeypox Vaccine Sales, by Country N (2022-2027)
  • Table 313. Asia Pacific Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 314. Asia Pacific Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 315. Asia Pacific Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 316. China Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 317. China Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 318. China Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 319. Japan Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 320. Japan Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 321. Japan Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 322. India Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 323. India Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 324. India Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 325. South Korea Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 326. South Korea Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 327. South Korea Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 328. Taiwan Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 329. Taiwan Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 330. Taiwan Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 331. Australia Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 332. Australia Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 333. Australia Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 334. Rest of Asia-Pacific Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 335. Rest of Asia-Pacific Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 336. Rest of Asia-Pacific Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 337. Europe Monkeypox Vaccine Sales, by Country N (2022-2027)
  • Table 338. Europe Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 339. Europe Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 340. Europe Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 341. Germany Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 342. Germany Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 343. Germany Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 344. France Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 345. France Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 346. France Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 347. Italy Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 348. Italy Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 349. Italy Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 350. United Kingdom Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 351. United Kingdom Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 352. United Kingdom Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 353. Rest of Europe Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 354. Rest of Europe Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 355. Rest of Europe Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 356. MEA Monkeypox Vaccine Sales, by Country N (2022-2027)
  • Table 357. MEA Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 358. MEA Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 359. MEA Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 360. Middle East Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 361. Middle East Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 362. Middle East Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 363. Africa Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 364. Africa Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 365. Africa Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 366. North America Monkeypox Vaccine Sales, by Country N (2022-2027)
  • Table 367. North America Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 368. North America Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 369. North America Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 370. United States Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 371. United States Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 372. United States Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 373. Canada Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 374. Canada Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 375. Canada Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 376. Mexico Monkeypox Vaccine Sales, by Application N (2022-2027)
  • Table 377. Mexico Monkeypox Vaccine Sales, by Symptoms N (2022-2027)
  • Table 378. Mexico Monkeypox Vaccine Sales, by End-use N (2022-2027)
  • Table 379. Research Programs/Design for This Report
  • Table 380. Key Data Information from Secondary Sources
  • Table 381. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Monkeypox Vaccine: by Application USD Million (2016-2021)
  • Figure 5. Global Monkeypox Vaccine: by Symptoms USD Million (2016-2021)
  • Figure 6. Global Monkeypox Vaccine: by End-use USD Million (2016-2021)
  • Figure 7. South America Monkeypox Vaccine Share (%), by Country
  • Figure 8. Asia Pacific Monkeypox Vaccine Share (%), by Country
  • Figure 9. Europe Monkeypox Vaccine Share (%), by Country
  • Figure 10. MEA Monkeypox Vaccine Share (%), by Country
  • Figure 11. North America Monkeypox Vaccine Share (%), by Country
  • Figure 12. Global Monkeypox Vaccine: by Application N (2016-2021)
  • Figure 13. Global Monkeypox Vaccine: by Symptoms N (2016-2021)
  • Figure 14. Global Monkeypox Vaccine: by End-use N (2016-2021)
  • Figure 15. South America Monkeypox Vaccine Share (%), by Country
  • Figure 16. Asia Pacific Monkeypox Vaccine Share (%), by Country
  • Figure 17. Europe Monkeypox Vaccine Share (%), by Country
  • Figure 18. MEA Monkeypox Vaccine Share (%), by Country
  • Figure 19. North America Monkeypox Vaccine Share (%), by Country
  • Figure 20. Global Monkeypox Vaccine share by Players 2021 (%)
  • Figure 21. Global Monkeypox Vaccine share by Players (Top 3) 2021(%)
  • Figure 22. Global Monkeypox Vaccine share by Players (Top 5) 2021(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Emergent BioSolutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Emergent BioSolutions Inc. (United States) Revenue: by Geography 2021
  • Figure 26. Wyeth Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Wyeth Laboratories, Inc. (United States) Revenue: by Geography 2021
  • Figure 28. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 29. Bavarian Nordic (Denmark) Revenue: by Geography 2021
  • Figure 30. Sanofi Pasteur Biologics LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Sanofi Pasteur Biologics LLC. (United States) Revenue: by Geography 2021
  • Figure 32. Chimerix (United States) Revenue, Net Income and Gross profit
  • Figure 33. Chimerix (United States) Revenue: by Geography 2021
  • Figure 34. Nanotherapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Nanotherapeutics (United States) Revenue: by Geography 2021
  • Figure 36. SIGA Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 37. SIGA Technologies (United States) Revenue: by Geography 2021
  • Figure 38. TapImmune (United States) Revenue, Net Income and Gross profit
  • Figure 39. TapImmune (United States) Revenue: by Geography 2021
  • Figure 40. Tonix Pharmaceuticals Holding (United States) Revenue, Net Income and Gross profit
  • Figure 41. Tonix Pharmaceuticals Holding (United States) Revenue: by Geography 2021
  • Figure 42. CEL-SCI (United States) Revenue, Net Income and Gross profit
  • Figure 43. CEL-SCI (United States) Revenue: by Geography 2021
  • Figure 44. Global Monkeypox Vaccine: by Application USD Million (2022-2027)
  • Figure 45. Global Monkeypox Vaccine: by Symptoms USD Million (2022-2027)
  • Figure 46. Global Monkeypox Vaccine: by End-use USD Million (2022-2027)
  • Figure 47. South America Monkeypox Vaccine Share (%), by Country
  • Figure 48. Asia Pacific Monkeypox Vaccine Share (%), by Country
  • Figure 49. Europe Monkeypox Vaccine Share (%), by Country
  • Figure 50. MEA Monkeypox Vaccine Share (%), by Country
  • Figure 51. North America Monkeypox Vaccine Share (%), by Country
  • Figure 52. Global Monkeypox Vaccine: by Application N (2022-2027)
  • Figure 53. Global Monkeypox Vaccine: by Symptoms N (2022-2027)
  • Figure 54. Global Monkeypox Vaccine: by End-use N (2022-2027)
  • Figure 55. South America Monkeypox Vaccine Share (%), by Country
  • Figure 56. Asia Pacific Monkeypox Vaccine Share (%), by Country
  • Figure 57. Europe Monkeypox Vaccine Share (%), by Country
  • Figure 58. MEA Monkeypox Vaccine Share (%), by Country
  • Figure 59. North America Monkeypox Vaccine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Emergent BioSolutions Inc. (United States)
  • Wyeth Laboratories, Inc. (United States)
  • Bavarian Nordic (Denmark)
  • Sanofi Pasteur Biologics LLC. (United States)
  • Chimerix (United States)
  • Nanotherapeutics (United States)
  • SIGA Technologies (United States)
  • TapImmune (United States)
  • Tonix Pharmaceuticals Holding (United States)
  • CEL-SCI (United States)
Additional players considered in the study are as follows:
EpiVax (United States) , Oncovir (United States) , Symphogen (Denmark)
Select User Access Type

Key Highlights of Report


Jul 2022 239 Pages 56 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Monkeypox Vaccine Market Quantitative research analysis
Global Monkeypox Vaccine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Monkeypox Vaccine Market are Emergent BioSolutions Inc. (United States), Wyeth Laboratories, Inc. (United States), Bavarian Nordic (Denmark), Sanofi Pasteur Biologics LLC. (United States), Chimerix (United States), Nanotherapeutics (United States), SIGA Technologies (United States), TapImmune (United States), Tonix Pharmaceuticals Holding (United States) and CEL-SCI (United States) etc.
Adult segment in Global market to hold robust market share owing to "High Prevalence of Infectious Diseases ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Monkeypox Vaccine market throughout the forecasted period.

Know More About Global Monkeypox Vaccine Market Report?

Have a Query? Click Here

Other Related Reports

Pediatric Digestive Drugs Comprehensive Study by Type (Global Pediatric Digestive Drugs Market Segment Percentages, by Type, 2021 (%)), Application (Gastroenteritis, Celiac disease, Crohn’s disease, ...
$ 3800
CBG Oil Comprehensive Study by Application (Skincare treatment, Mental Health treatment, Physical Health treatment, Other), Bottle (15ml, 30ml, Other), Mg (100mg -500mg, 600mg – 1100mg, 1200mg-1700mg...
$ 3800
Birthmarks Drugs Comprehensive Study by Application (Hospitals, Pharmaceuticals, Clinical laboratories), Forms (Tablets, Ointment, Powder, Liquid), Disease (Strawberry hemangiomas, Cavernous hemangio...
$ 3800
Hormone Deficiency Comprehensive Study by Application (Hospitals, Clinics), Medication (Genotropin, Humatrope, Norditropin, Other), Types of Hormonal Disorders (Adrenal, Parathyroid, Pancreas, Pituit...
$ 3800
Stephania Extract Comprehensive Study by Type (Tablet, Capsule, Injection), Distribution Channel (Online, Offline), End User (Household, Hospital, Clinic, Pharmaceutical, Others) Players and Region -...
$ 3500
Probiotics Based Dietary Supplement Comprehensive Study by Type (Capsules and Pills, Powders, Fermented Foods), Application (Immune System Support, Vaginal Health, Skin Health), Form (Capsules, Chewa...
$ 3800